share_log

Stifel Downgrades Orchard Therapeutics to Hold, Announces $16 Price Target

Benzinga ·  Oct 5, 2023 10:36

Stifel analyst Dae Gon Ha downgrades Orchard Therapeutics (NASDAQ:ORTX) from Buy to Hold and announces $16 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment